Atomo NewsGet the app

Get the latest Science News and Discoveries

Insilico Medicine nominates ISM0900, a potent, AI-driven, oral Lp(a) inhibitor, as PCC for management of cardiovascular risks - EurekAlert!


Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of Cardiovascular Risks

Cardiovascular Risks

Photo of management

management

Photo of Insilico Medicine

Insilico Medicine

Related news:

News photo

Science Signaling | Insilico Medicine contributes to research using AI to reveal NDRG1-associated DNA repair mechanisms and potential synthetic lethal effects in colorectal cancer - EurekAlert!

News photo

AI-empowered pipeline-in-a-drug option: Insilico Medicine nominates ISM9077, potential first-in-class target Y inhibitor, as preclinical candidate (PCC) for ocular diseases, inflammatory disorders and aging - EurekAlert!

News photo

Insilico Medicine receives NMPA IND clearance for innovative oral candidate ISM8969/HT-001, the brain-penetrant NLRP3 inhibitor co-developed with Hygtia Therapeutics - EurekAlert!

« Just three water molecules: Scientists discover the minimal “structural switch” that unlocks ultrafast proton transport - EurekAlert!
High-purity linearly polarized emission from a compact BIC laser - EurekAlert! »